

I hereby certify that this correspondence is being filed via
EFS-Web with the United States Patent and Trademark Office
on December 20, 2006.

TOWNSEND and TOWNSEND and CREW LLP

By: /Anna C. Kundel/
Anna C. Kundel

PATENT
Attorney Docket No.: 015280-342100US
Client Reference No.: E-019-1998/0-US-
06

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

KASLOW et al.

Application No.: 09/554,960

Filed: February 12, 2003

For: VACCINES FOR BLOCKING
TRANSMISSION OF PLASMODIUM
VIVAX

Confirmation No.: 6829

Examiner: Lieto, Louis D.

Art Unit: 1632

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER
37 CFR §1.97 and §1.98

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are not enclosed as they were filed with the application on February 12, 2003. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Also enclosed is a copy of the Search/Examination report corresponding to the PCT application.

As provided for by 37 CFR §1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

/Jennifer L. Wahlsten/

Jennifer L. Wahlsten
Reg. No. 46,226

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
JLW:ack
60944525 v1

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/554,960
				Filing Date	February 12, 2003
				First Named Inventor	Kaslow, David C.
				Art Unit	1632
				Examiner Name	Lieto, Louis D.
Sheet	1	of	1	Attorney Docket Number	015280-342100US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	1	WO	89/10936	A1	11-16-1989	The United States of America as represented by the Secretary, U.S. Department of Commerce		<input type="checkbox"/>
	2	WO	94/01552	A1	01-20-1994	The United States of America, as represented by the Secretary of the Department of Health and Human Services		<input type="checkbox"/>
	3	WO	94/28930	A1	12-22-1994	Virogenetics Corporation		<input type="checkbox"/>
	4	WO	95/08631	A2	03-30-1995	The Government of the United States of America, represented by the Secretary of the Department of Health and Human Services		<input type="checkbox"/>
	5	WO	98/14472	A1	04-09-1998	The Government of the United States of America as represented by the Secretary, Department of Health and Human Services		<input type="checkbox"/>

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	6	AGABIAN N., et al., "Molecular strategies of parasitic invasion," Alan R. Liss, Inc., (1987), see MENDIS, K. et al., "Immune modulation of parasite transmission in <i>Plasmodium vivax</i> malaria: Anti-gamete antibodies can both block and enhance transmission"; <u>Molecular Strategies of Parasitic Invasion</u> ; pp. 417-426, 1987. Alan R. Liss, Inc.	<input type="checkbox"/>
	7	PREMAWANSA, S. et al., "Target antigens of transmission blocking immunity of <i>Plasmodium vivax</i> malaria: Characterization and polymorphism in natural parasite isolates"; <u>J. Immunol.</u> Vol. 144 (11), pp. 4376-4383 (June 1, 1990)	<input type="checkbox"/>
	8	SNEWIN, V. et al., "Transmission blocking immunity in <i>Plasmodium vivax</i> malaria: Antibodies raised against a peptide block parasite development in the mosquito vector"; <u>J. Exp. Med.</u> , Vol. 181, pp. 357-362 (January 1995)	<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.